MedTrace Logo

TMC207 +/- Rifabutin/Rifampin

NCT01341184 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-04-21

No results posted yet for this study

Summary

Evaluation of effect of rifampin or rifabutin on single dose PK of TMC207 in healthy volunteers

Conditions

Interventions

DRUG

Rifabutin

Rifabutin 300 mg orally on days 20-41

DRUG

Rifampin

Rifampin 600 mg orally on days 20-41

DRUG

TMC207

TMC207 400 mg orally on days 1 and 29

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-21
Primary Completion
2012-05-23
Completion
2012-05-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341184 on ClinicalTrials.gov